Blood levels of Glial Fibrillary Acidic protein (GFAP) reflect processes associated with different types of CNS injury. Evidence suggests that GFAP is cleaved by caspases during CNS injury, hence positioning GFAP fragments as potential biomarkers of injury-associated processes. We set out to develop...
November 6, 2019
Journal:
PLoS One
Author:
Jonesco DS, Hassager C, Frydland M, Kjærgaard J, Karsdal MA, Henriksen K
BACKGROUND: Truncated tau appears to be specifically related to disease pathology and recent studies have shown the presence and elevation of several truncated tau species in Cerebrospinal fluid (CSF) of subjects with Alzheimer\u0027s disease (AD); however, the relevance of truncated Tau measurement...
April 11, 2018
Journal:
PLoS One
Author:
Neergaard JS, Dragsbæk K, Christiansen C, Karsdal MA, Brix S, Henriksen K
Cerebral non-oxidative carbohydrate consumption may be driven by a β2-adrenergic mechanism. This study tested whether the 46G \u003e A (G16R) single nucleotide polymorphism of the β2-adrenergic receptor gene (ADRB2) influences the metabolic and cerebrovascular responses to administration of adrenali...
September 5, 2017
Journal:
Front Physiol
Author:
Rokamp KZ, Staalsø JM, Zaar M, Rasmussen P, Petersen LG, Nielsen RV, Secher NH, Olsen NV, Nielsen HB
To evaluate whether muscle vasodilatation plays a role for hypotension developed during central hypovolaemia, muscle oxygenation (Sm O2 ) was examined during (pre)syncope induced by head-up tilt (HUT). Skin blood flow (SkBF) and oxygenation (Sskin O2 ) were determined because evaluation of Sm O2 may...
September 1, 2017
Journal:
Acta Physiol (Oxf)
Author:
Lund A, Sørensen H, Jensen TW, Niemann MJ, Olesen ND, Nielsen HB, Olsen NV, Secher NH
There has been limited success with blood-based biomarkers of neurodegeneration. One perceived reason is that blood has no direct contact to the brain. Recently developed blood-based biomarkers of tau-degradation have shown promise as potential tools for peripheral assessment of neurodegeneration; h...
May 10, 2017
Journal:
Neurochem Int
Author:
Karsdal MA, Henriksen K, Brix S, Workman CT, Nielsen HB, Christiansen C, Dragsbæk K, Neergaard JS
In healthy humans, stroke volume (SV) and cardiac output (CO) do not increase with expansion of the central blood volume by head-down tilt or administration of fluid. Here, we exposed 85 patients to Trendelenburg\u0027s position about one hour after surgery while cardiovascular variables were determ...
BACKGROUND:The mechanisms underlying red blood cell (RBC)-mediated hypoxic vasodilation remain controversial, with separate roles for nitrite () and S-nitrosohemoglobin (SNO-Hb) widely contested given their ability to transduce nitric oxide bioactivity within the microcirculation. To establish their...
January 10, 2017
Journal:
Circulation
Author:
Bailey DM, Rasmussen P, Overgaard M, Evans KA, Bohm AM, Seifert T, Brassard P, Zaar M, Nielsen H, Raven PB, Secher NH
The last decade has seen a substantial increase in research focused on the identification of blood-based biomarkers that have utility in Alzheimer's disease (AD). Blood-based biomarkers have significant advantages of being time- and cost-efficient as well as reduced invasiveness and increased patien...
November 18, 2016
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Mielke MM, Rissman RA, Lista S, Vanderstichele H, Zetterberg H, Lewczuk P, Posner H, Hall J, Johnson L, Fong YL, Luthman J, Jeromin A, Batrla-Utermann R, Villarreal A, Britton G, Snyder PJ, Henriksen K, Grammas P, Gupta V, Martins R, Hampel H
Differential diagnosis of AD is still a challenge due to overlapping features with other types of dementia. Biomarkers for the differential diagnosis of AD can improve the diagnostic value of the disease and ensure an appropriate treatment of patients. The aim of this study was to evaluate the poten...
July 10, 2015
Journal:
Curr Alzheimer Res
Author:
Inekci D, Henriksen K, Linemann T, Karsdal MA, Habib A, Bisgaard C, Eriksen FB, Vilholm OJ
Enzyme-generated fragments of tau have been linked to neuronal death and may serve as serum biomarkers of cognitive loss. Two competitive ELISAs detecting an ADAM10-generated fragment (Tau-A) or a caspase-3-generated fragment (Tau-C) were measured in baseline serum samples from patients with mild to...
June 11, 2015
Journal:
Int J Alzheimers Dis
Author:
Henriksen K, Byrjalsen I, Christiansen C, Karsdal MA
The lack of readily available biomarkers is a significant hindrance toward progressing to effective therapeutic and preventative strategies for Alzheimer's disease (AD). Blood-based biomarkers have potential to overcome access and cost barriers and greatly facilitate advanced neuroimaging and cerebr...
May 11, 2015
Journal:
Alzheimers Dement
Author:
O'Bryant SE, Gupta V, Henriksen K, Edwards M, Jeromin A, Lista S, Bazenet C, Soares H, Lovestone S, Hampel H, Montine T, Blennow K, Carrillo M, Graff-Radford N, Laske C, Breteler M, Shaw L, Trojanowski JQ, Schupf N, Rissman RA, Fagan AM, Oberoi P, Umek R, Weiner MW, Grammas P, Posner H, Martins R
The diagnosis of dementia is challenging and early stages are rarely detected limiting the possibilities for early intervention. Another challenge is the overlap in the clinical features across the different dementia types leading to difficulties in the differential diagnosis. Identifying biomarkers...
Treatment of Alzheimer's disease (AD) is significantly hampered by the lack of easily accessible biomarkers that can detect disease presence and predict disease risk reliably. Fluid biomarkers of AD currently provide indications of disease stage; however, they are not robust predictors of disease pr...
January 10, 2014
Journal:
Alzheimers Dement
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) ...
December 12, 2012
Journal:
Int J Alzheimers Dis
Author:
Wang Y, Sørensen MG, Zheng Q, Zhang C, Karsdal MA, Henriksen K
Drug development for dementias is significantly hampered by the lack of easily accessible biomarkers. Fluid biomarkers of dementias provide indications of disease stage, but have little prognostic value, cannot detect early pathological changes, and can only be measured in CSF (cerebrospinal fluid) ...
December 12, 2012
Journal:
Int J Alzheimers Dis
Author:
Wang Y, Sørensen MG, Zheng Q, Zhang C, Karsdal MA, Henriksen K
Search and find publications that we have published.
Please don't hesitate to contact us if you have any questions or other inquiries.
We use cookies on our site to enable essential services and functionalities, and collect data in regards to visitor information. This is done in order to provide the best possible experience for the visitor. Cookie policy Privacy statement
